Clinical Trial

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2021-10-21; most recent amendment 2026-02-11.
Status change: Not Yet Recruiting → Recruiting 2021-12-01
Trial Details
NCT Number NCT05103683
Lead Sponsor TORL Biotherapeutics, LLC
Collaborators: Translational Research in Oncology
Conditions Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
Enrollment 90 participants
Start Date 2021-11-17
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-02-13